MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Precision Medicine Tools to Physicians

Predictive Oncology (NASDAQ: POAI) is assisting clinicians and researchers in improving outcomes for cancer patients via its AI-driven, tumor-profiling platform. A recent article discussing the company reads, “POAI’s technology combines its database of evidence documenting actual drug responses of cancer patients’ tumors with artificial intelligence (AI) to create an invaluable predictive tool for clinicians and researchers. Predictive Oncology’s data offers a valuable, customizable assessment method that can be used by oncologists to determine the best drug for fighting a specific patient’s cancer. This disruptive technology is the first of its kind and is also meeting a critical need in the pharmaceutical, diagnostic and biotech industries to speed up the search for new precision therapies by providing tools to better predict how new drugs work on different cancers (http://ibn.fm/0YnNI). . . . POAI’s wholly owned subsidiaries — Helomics and TumorGenesis — are working together to bring these important precision-medicine tools to physicians.”

To view the full article, visit http://ibn.fm/7xJbm

About Predictive Oncology Inc.

Predictive Oncology (formerly Precision Therapeutics Inc.) operates through its three business units: Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Advances Within Competitive Canadian Cannabis Space

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium certified-organic cannabis, is on a mission to meet the growing demand for organic cannabis in Canada. An article discussing the company reads, “Recently, TGOD received a 100% organic rating from Toronto-based Corporate Knights magazine (http://ibn.fm/B0fNJ). The company is one of the few in Canada licensed to cultivate organic cannabis. The Green Organic Dutchman is a pioneer in shifting from indoor farming to greenhouse cultivation, making use of solar energy and cutting electricity costs by up to 90%. Companies leading this effort are using glass-roofed greenhouses equipped with the latest high-tech equipment to produce ‘sun-grown’ organic cannabis (http://ibn.fm/r7uCv).”

To view the full article, visit http://ibn.fm/G4dcf

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings is a publicly traded, premium, global, organic-cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic-hemp, CBD-oil operations in Canada and, through its wholly owned subsidiary HemPoland, distributes premium-hemp CBD oil in the EU. The company grows high-quality, certified-organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned global capacity of 219,000 kgs. and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Patented PCT Platform Highlighted in 10 Separate Presentations at International Human Proteome Organization World Congress

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its patented pressure cycling technology (“PCT”) platform was prominently featured at the International Human Proteome Organization World Congress (“International HUPO”) in no less than ten separate presentations from scientists affiliated with seventeen leading research institutions worldwide. “We believe the unique value provided by our PCT platform for cancer research and diagnostics, which was broadly highlighted across ten presentations at this important international human protein conference, will help to accelerate awareness and adoption for our unique PCT sample preparation platform across multiple large and growing markets. Subsequently, we believe this increased awareness and conversion into adoption will result in increased sales of our PCT instruments and consumables in Q4 2019 and beyond,” Pressure BioSciences Global Director of Sales & Marketing Roxana McCloskey stated in the news release.

To view the full press release, visit http://ibn.fm/qfDwh

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

ChineseInvestors.com Inc. (CIIX) MicroCap Presentation Well Received, CBD Future Bright

• CIIX CEO Warren Wang reported that MicroCap Conference attendees showed interest in the company’s presentation
• In a MoneyTV interview, Wang expressed optimism about the long-range sales of CBD; CIIX will focus on the CBD cosmetics sector
• CIIX reported a 175 percent YOY sales increase for FY2019; industrial hemp and CBD liquor products showed sharp gains

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang said in a MoneyTV interview with host Donald Baillargeon that he was pleased with the reaction to the company’s presentation at the MicroCap Conference, held recently at the Essex House in New York. The presentation was given by Alex Hamilton, CFO of CIIX subsidiary Biotech CBD Inc. (http://ibn.fm/P1TVf).

The conference was designed to bring together high-level institutional and retail investors with publicly held small- and micro-cap companies. Wang noted that he is optimistic about the long-term growth of CBD sales and said that, moving forward, the company plans to focus on cosmetics in the category. According to New Frontier Data, the U.S. hemp CBD market is expected to triple in value by 2022. Likewise, according to Hemp Industry Daily market projections, the national market for hemp-derived CBD is expected to balloon to $7 billion by 2023 (http://ibn.fm/1uxPo).

In addition, CIIX reported sharp gains of 175 percent year-over-year for its FY2019, ended in May 2019. That gain was generated by FY2019 sales of $6,476,442, as compared to $2,353,331 in FY2018, according to its 10-K SEC filing (http://ibn.fm/LIZnq). The increase was driven by industrial-hemp and CBD-liquor product sales of $4,189,935 in FY2019, as compared to $378,984 in FY2018 (http://ibn.fm/PO4wS). Investor relations, a core business for the company, generated gains as well, with sales totaling $1,336,402 in FY2019, as compared to $968,282 the prior year.

Earlier, Wang projected that CIIX sales will reach $11 million to $12 million in FY2020 – the 12 months ending in May 2020. That projection was made during a wide-ranging interview on the Redchip Money Report with host Dave Gentry, broadcast on YouTube. The company has long been reaching a Chinese-speaking audience in the United States and Canada with investment information on issues ranging from cryptocurrency to CBD.

In the same interview, Wang also noted that investors should know that CIIX is seeking to expand its future business. “We are going to do some merger/acquisition to expand our business in the Asian region,” he told the host.

CIIX is a diverse company driven not only by educational services but also by sales of cosmetics, hemp wine and CBD. CIIX offers its audience of Chinese-speaking investors real-time market commentary, analysis and education-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Chief Marketing Officer Recognized on Forbes CMO Next List

Lifestyle-oriented cannabis company Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) today announced that Jann Parish, Chief Marketing Officer, has been named to the Forbes CMO Next list, a list comprised of 50 individuals considered to be leading the way as disruptive chief marketers. Established through qualitative research and editorial industry knowledge, the Forbes list features executives in the top marketing position at their company that push brand and business growth. Through Parish’s leadership the company has opened over 130 Seventh Sense CBD shops, expanded Seventh Sense’s digital reach, increased sales and margin figures in its Nevada The+Source dispensary business by double digits and prepared for the October launch of a new CBD brand, Green Lily. “I am honored and humbled to receive this recognition,” Green Growth Brands CMO Jann Parish stated in the news release. “I am thrilled to be applying my expertise to the cannabis and CBD industries. At Green Growth Brands, we look at this moment in time as an opportunity to reinvent the way consumers view and interact with products that have very complicated histories. For Forbes to be considering our industry as part of this award speaks to the progress we have already made.”

To view the full press release, visit http://ibn.fm/qa5za

About Green Growth Brands

Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The company also has a licensing agreement with the Greg Norman(TM) Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S. its CBD presence at ShopSeventhSense.com, in malls across the country, at DSW and Abercrombie & Fitch stores—and that’s just the beginning. For more information, visit the company’s website at www.GreenGrowthBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to GGBXF are available in the company’s newsroom at http://ibn.fm/GGBXF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Pressure BioSciences Inc.’s (PBIO) Proprietary Technology Platform Identified as Key Cancer Biomarker Research Element

• Independent research carried out by Chinese and Australian scientists shows that the Pressure BioSciences Pressure Cycling Technology (PCT) platform is excellent for the processing of preserved (formalin-fixed paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are considered invaluable for discovering cancer biomarkers
• Such tissues play a pivotal role in cancer research and may potentially contribute to the development of therapies and prevention protocols
• Cancer research is one of the more rapidly growing sectors making use of PBIO’s technology; to prepare for further expansion in the future, the company has appointed a new, highly experienced chief financial officer
• The company recently announced that Daniel J. Shea has joined the team as chief financial officer and senior vice president, in anticipation of growth

Pressure BioSciences Inc.’s (OTCQB: PBIO) novel and powerful Pressure Cycling Technology (PCT) platform has performed excellently during the processing of preserved (FFPE) and fresh frozen biopsy tissue samples for the discovery of cancer biomarkers, as indicated by two recently published scientific articles about the technology’s performance.

Independent teams of scientists from China and Australia led the research, and their data suggest that the Pressure BioSciences technology could potentially be used in the clinical diagnostic process based on the cancer biomarkers, as the company noted in a press release (http://ibn.fm/DfmC7). Chinese researchers purchased their first two PCT platforms in 2017 and subsequently purchased four additional systems. In Australia, the PCT platform has been in use since 2016.

Because of the large amount of support data on preserved tissue samples like the ones used in the Chinese and the Australian research studies, such samples are considered invaluable for the retrospective study of disease progression and response to therapy. The use of such samples could speed up the discovery of new therapies and preventative strategies, but, up until now, the successful extraction of high-quality biomolecules from FFPE samples has been difficult to accomplish, at best.

According to Pressure BioSciences president and CEO Richard T. Schumacher, over one billion archival tissue samples exist in pathology and other laboratories across the world. Millions of additional samples are processed and stored every single year. These samples contain an abundance of information that could be key to the discovery of new cancer biomarkers, development of new cancer diagnostics, and release of new treatments and prevention measures, Schumacher concluded.

“We believe that our PCT platform is establishing itself as the method of choice for the superior extraction of potential biomarkers and their presentation for the effective proteomic analyses that will propel the growth of this huge market,” Pressure BioSciences’ director of marketing and sales Roxana McCloskey added.

The global cancer biomarker market is anticipated to reach more than $157 billion by 2022. This is just one of the multiple important applications of Pressure BioSciences’ innovative pressure-based technology platform.

To prepare for the anticipated growth in the years to come, Pressure BioSciences announced a strategic team addition on September 17, 2019. According to an official company announcement, Daniel J. Shea has joined the team as chief financial officer and senior vice president (http://ibn.fm/3rLyE).

Shea has over 30 years of experience in leading and advising financial organizations. Since the beginning of 2017, Shea has operated a CPA advisory firm called Woodcliff Advisors LLC, which provides counsel to boards, CFOs and members of senior management teams.

“PBIO’s unique platform technologies, worldwide customer base, growing revenue stream, and strong management team position the company well to capitalize on substantial growth opportunities across the globe. I stand ready to support the company’s commitment to high-quality financial reporting and internal control as it navigates through these opportunities in the coming years,” Shea said, commenting on the appointment.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Powdered Formulation of CBD-Rich Hemp Oil Now Available to US Consumers

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently launched its ChrgD+ product, a water-soluble, multispectrum hemp oil in a powdered format powered by the company’s proprietary DehydraTECH(TM) technology for rapid CBD delivery (http://ibn.fm/Ljt7D). An article discussing the company reads, “The rapid biodelivery of CBD through DehydraTECH provides an avenue for safer, less-conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare. . . . ChrgD+ has been available in a limited number of retail stores throughout the Western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life  without having to travel. Limited-time promotional offers and product updates are also available through the site.”

To view the full article, visit http://ibn.fm/8mNmZ

About Lexaria Bioscience Corp.

Lexaria is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and more than 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Confirms Robust Demand for Premium Organic Cannabis

• The Green Organic Dutchman produces high-quality, organic cannabis for the medicinal and recreational adult use markets from purpose-built, state-of-the-art facilities
• The company has confirmed higher demand for premium organic cannabis
• TGOD has also announced positive results from its pharmacokinetic study of innovative cannabinoid technology

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is an international, premium organic cannabis company based in Mississauga, Ontario. The company produces high-quality, organic medical and recreational adult use cannabis using organic craft growing principles. TGOD plans on commercializing organic cannabinoid dissolvables in Canada beginning in December 2019 under the TGOD-Infusers line of premium cannabis products, and results from a recent study have given support to that move. Additionally, TGOD was able to report strong demand for its premium organic cannabis following its Ontario launch and fast-tracked shipments.

Following its Ontario launch and fast-tracked shipments, TGOD reported that there is a strong demand for its premium organic cannabis (http://ibn.fm/wOW3S). After the August launch, initial demand surpassed expectations. The company’s high-THC (tetrahydrocannabinol) signature strain, Unite Organic, performed well both online and at dispensaries, resulting in a second order from the Ontario Cannabis Store – earlier than initially anticipated. The strong launch marks TGOD’s successful entrance into the Canadian recreational market.

While cannabis companies abound, TGOD continues to impress with its organic emphasis and the overall quality of its products. TGOD’s cannabis is grown in its proprietary living soil, in accordance with all-natural principles. Moreover, its growing process is certified organic by Pro-Cert and ECOCERT, two top organic certification bodies. Of note is the fact that, according to a 2019 study conducted by Hill & Knowlton, more than 50 percent of recreational consumers intending to purchase cannabis stated that it is important that their cannabis be organic, and over 60 percent of medical patients prefer organic cannabis. As one of the few certified-organic companies in Canada, these numbers give TGOD an edge in the market.

While TGOD’s premium cannabis products are thriving, the company also plans on introducing organic CBD-dissolvables to the market. In line with that goal, TGOD and Caliper Foods recently reported positive results from a pharmacokinetic study of proprietary, water-soluble cannabinoid technology (http://ibn.fm/JdgjH). The two companies revealed the results of a preliminary human pharmacokinetic (PK) study of Caliper CBD, Caliper Foods’ proprietary tasteless, odorless, water-soluble powder, which can be added to almost any food or beverage. Caliper Foods is a best-in-class provider of water-soluble cannabinoid products.

In the study, half of the participants were administered 30 milligrams of Caliper Foods’ water-soluble CBD powder in eight ounces of water; the other half received 30 milligrams of CBD dispersed in MCT oil. Early data shows that the group that received Caliper CBD demonstrated speedier onset within 15 minutes, with higher concentrations attained at 15 minutes versus the maximum concentration attained at 45 minutes with the CBD-in-oil formulation, and a 4.5-fold higher observed total bioavailability.

“We are thrilled with the results of this preliminary PK study, which demonstrate the consistency and precision of Caliper Foods’ proven proprietary technology, which is already available in Colorado and which TGOD will commercialize in Canada,” TGOD Chief Science Officer Dr. Rav Kumar stated in a news release (http://ibn.fm/J5bPQ). “Based on this early data, Caliper CBD provides a higher and faster absorption level when compared with CBD-infused oil, which opens a number of possibilities for both the medical and adult-use markets.”

With its proven management team and state-of-the-art facilities, TGOD continues to focus on providing a slate of premium consumer-preferred products. The company offers investors potential return on investment as it looks to grow via strategic international opportunities. TGOD’s hybrid facilities represent important advantages over indoor and outdoor greenhouses and set the stage for lower capex and greater profits.

TGOD’s operational emphasis is on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. The company’s strategy is to grow organically and at low costs, resulting in a product that demands a premium in the marketplace, thereby increasing the company’s margins.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Earth Science Tech Inc. (ETST) Expands in the CBD Space, Establishes New Sales Unit

• Earth Science Tech has launched a new sales division focused on CBD, led by Industry-veteran Erika Franck
• ETST’s portfolio is positioned in the dually lucrative biotechnology and cannabis/cannabidiol industries
• Biotechnology currently represents the largest segment of the growing legal cannabis market

Earth Science Tech Inc. (OTCQB: ETST) recently launched a new sales unit to further strengthen its position in the CBD marketplace for medical and pharmaceutical products. Erika Franck, who has previously served as the company’s clinical and therapeutics sales director, will be heading the division. ETST made this move in accordance with the growing use of CBD in the licensed medical fields and alternate medicinal streams.

The company, under the leadership of Franck, will target medical experts and specialists, suppliers, acupuncturists, chiropractors, practitioners of holistic wellness and alternative therapies, and veterinarians. With the appointment of Franck, the company receives her sound knowledge and experience in the pharmaceutical and orthopedics industry.

“I am thrilled to be part of this amazing team and to have the opportunity to apply my expertise in spearheading this new clinical division for ETST,” Franck stated in a news release (http://ibn.fm/Q84nZ). “Our shared vision is to improve patients’ quality of life, and I am honored to participate in ETST’s continued growth as we achieve this mission.”

Earth Science Tech is well-positioned as a biotechnology company which focuses on the research and development of CBD, pharmaceuticals and medical device products. The company’s pure CBD oil is manufactured using CO2 liquid extraction processes; ETST prides itself on offering the finest quality pure CBD oil on the market.

The biotechnology segment of the cannabis industry consists of pharmaceutical firms focused on the research and development behind new drugs and products that utilize cannabinoids, which are the active compounds within cannabis. Currently the largest sector in the legal cannabis market, it is expected to see further growth as more entities around the world continue researching cannabinoids (http://ibn.fm/icNh9). This trend is encouraging for biotechnology companies like Florida-based ETST.

ETST projects a robust portfolio through its two wholly owned subsidiaries, which are focused on the research and production of cutting-edge industrial hemp and cannabis/cannabidiol (CBD) products to take advantage of the potential seen in the burgeoining cannabis industry.

ETST subsidiary Earth Science Pharma Inc. is engaged in the production of noninvasive economical diagnostic testing tools, medical devices and vaccines for sexually transmitted infections and/or diseases. Their first STI home detection kit using a modified panty liner (MSN-2), named Hygee, is a revolutionary product that can be used for chlamydia testing by women from their homes. The MSN-2 technology is further being utilized to screen for other STIs such as gonorrhea and thichomoniasis, and it holds disruptive potential in the women’s health sector.

Cannabis Therapeutics Inc., another of ETST’s subsidiaries, was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis/cannabinoid-based pharmaceuticals, nutraceuticals and other products and solutions.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Highlighted in Editorial on Potential Breast Cancer Treatments

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its placement in an editorial published by NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers,” may be accessed via the following link: http://ibn.fm/FQ6yC. The editorial reads,“‘Disruptive’ isn’t a term that’s often applied to medicine, where the aim is to avoid disrupting the health of the human body. But technology such as Genprex Inc.’s (NASDAQ: GNPX) Oncoprex(TM) immunogene therapy is disruptive precisely because it could improve doctors’ ability to preserve health. It may also change the course of cancer, as new technology often opens up new possibilities.”

To view the full press release, visit http://ibn.fm/ISZ67

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – SRAX, Inc. (NASDAQ: SRAX) to Present at the 5th Annual B. Riley Consumer & Media Conference in NYC

Digital marketing and consumer data management technology company SRAX (NASDAQ: SRAX) today announced that it is scheduled to present at the 5th Annual B. Riley Consumer & Media Conference to be held at the Sofitel Hotel in New York City on Thursday, October 3, 2019. SRAX CEO Chris Miglino will participate in a fireside chat with analyst Mike Crawford at 1:00 p.m. Eastern Time on October 3^rd, and will host one-on-one meetings with investors throughout the day. Interested parties should contact their B. Riley representative to schedule a meeting.

To view the full press release, visit http://ibn.fm/bFRRC

About SRAX Inc.

SRAX is a digital marketing and consumer-data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) to Report Results, Host Earnings Conference Call for Q4 and Fiscal Year 2019

Lifestyle-oriented cannabis company Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) on Tuesday announced that it will report results for the fourth quarter and fiscal year 2019 ending June 30, 2019, on Wednesday, October 23, 2019, at approximately 5:00 PM ET. In addition, Green Growth Brands will host a conference call with company management in conjunction with release of its financial results, with the call slated to take place on Thursday, October 24, 2019, at 8:30 AM ET. Interested parties may join the conference by dialing (+1) 416 764 8609 (Local Toronto), (+1) 778 383 7417 (Local Vancouver) or (+1) 888 390 0605 (North American Toll-Free) and entering Conference ID: 66844833. The call and archived replay will be accessible on Green Growth Brands’ Investor Relations website.

To view the full press release, visit http://ibn.fm/Tzput

About Green Growth Brands

Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The company also has a licensing agreement with the Greg Norman(TM) Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S. its CBD presence at ShopSeventhSense.com, in malls across the country, at DSW and Abercrombie & Fitch stores—and that’s just the beginning. For more information, visit the company’s website at www.GreenGrowthBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to GGBXF are available in the company’s newsroom at http://ibn.fm/GGBXF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Youngevity International Inc. (NASDAQ: YGYI) Closes $8.3M Public Offering; Launches HEMP FX Brand in Japan

Youngevity International (NASDAQ: YGYI), a leading multi-channel lifestyle company operating in three distinct business segments, on Tuesday announced the closing of its underwritten public offering of 333,500 shares of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock, including 43,500 shares pursuant to the exercise of the over-allotment option by the underwriters. The shares were sold at a public offering price of $25.00 each, resulting in gross proceeds of $8,337,500, prior to withholding discount, commissions and estimated offering expenses. The Benchmark Company, LLC acted as sole book-running manager of the offering.

In addition, YGYI this morning announced the launch of Hemp FX in Japan. Hemp FX is a phytocannabinoid-rich hemp oil product line that includes three proprietary formulas featuring full-spectrum, organically grown hemp oil. Hemp FX Soothe, Hemp FX Capsules and Hemp FX Tincture have obtained the applicable approvals and are now available for purchase in Japan. “Hemp FX is an ideal representation of our plant-based approach to product development. These select products are being offered in this initial launch, and we expect the Hemp FX line will continue to grow, with more products becoming available for sale in Japan in the near future,” Youngevity CEO Steve Wallach stated in the news release. “This product launch has really been creating excitement in the Japanese market and we expect that it will provide significant growth within our distributor base in Japan.”

To view the full press releases, visit http://ibn.fm/dBC8i and http://ibn.fm/BKi9A

About Youngevity International Inc.

Youngevity International Inc. is a multi-channel lifestyle company operating in three distinct business segments, including a commercial coffee enterprise, a commercial hemp enterprise and a multi-vertical omni direct selling enterprise. The company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity; YGYI offers products from the six top-selling retail categories, including health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry and innovative services. For more information, visit the company’s website at www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Pressure BioSciences Inc. (PBIO) Issues Update on Guidance for Revenue Growth and Success of Revolutionary CBD Oil Processing System

• The company believes that its total revenue will more than double in 2020, led by commercialization of its revolutionary CBD oil nanoemulsification system
• PBIO’s BaroShear K45, based on the company’s proprietary Ultra Shear Technology (UST) platform, revolutionizes the manufacture of water-soluble, long-term, stable, highly absorbable, nanoemulsified CBD oil
• The worldwide CBD market is expected to reach $20 billion in sales by 2024, with competition ramping up as CBD manufacturers seek new ways to stand out
• PBIO has announced three pre-sales of its BaroShear K45 nanoemulsification system for making water-soluble CBD Oil
• Progress continues on the build-out of its GMP-compliant manufacturing laboratory to showcase the BaroShear K45 and its industrial scale, high volume UST-based nanoemulsification systems (release date to be determined)

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, expects its total revenues to more than double in 2020 following the successful launch of its revolutionary CBD (cannabidiol) processing system – the BaroShear K45. This novel processing system creates a water-soluble CBD oil that disperses instantly in liquid, providing enhanced quality and bio-absorption (http://ibn.fm/PSUr8).

Development of the BaroShear K45 system began following the company’s in-depth analysis of the CBD market, which showed a common, yet critical production issue facing CBD manufacturers – the poor water solubility of today’s oil-based CBD products means that the beneficial properties of CBD are inadequately available for absorption in the body.

“After much diligence and analysis, we concluded that we have the expertise and experience to successfully address this critical issue,” Richard T. Schumacher, president and CEO of PBIO, stated in an August 2019 shareholder report (http://ibn.fm/Ym0dG). “Consequently, we pulled significant hours away from many of our staff over the past few months and had them focus on the development of an instrument system – based on our patented UST platform – that would increase the water-solubility, and thus the absorption, of CBD Oil. We succeeded; the result of that success is the BaroShear K45 processing system.”

The collective market for CBD sales in the U.S. is expected to exceed $20 billion by 2024, according to a new report from BDS Analytics and Arcview Market Research (http://ibn.fm/RJsFW). The forecast includes products sold through licensed dispensaries and general retail outlets such as grocery stores, mass merchants and pharmacies. Standing out from the crowded field of competitors will be essential for any business pursuing the spotlight in a rapidly expanding CBD marketplace.

“To survive, companies will need to differentiate themselves from the competition by delivering the highest quality products possible,” Schumacher added. “Such products would undoubtedly need to have high water-solubility, absorption, and bioavailability, along with long shelf-life and a minimal amount of added chemicals. This is exactly what we intend to deliver.”

PBIO announced the initial sale of the BaroShear K45 processing system to its first customer, Nano CBD Cosmetics LLC, in an earlier news release (http://ibn.fm/XSn75). Nano CBD Cosmetics founder and CEO Christopher Holden expressed excitement with his company’s purchase.

“We are thrilled to be the first purchaser of the BaroShear K45 system,” Holden stated in the release. “This groundbreaking technology will enable companies producing nano-scale CBD emulsion products to meet the ever-increasing demand for CBD nanoemulsion products. In fact, our own nano-CBD products are currently selling faster than we can produce them. However, with PBIO’s cutting-edge technology, we expect to increase our nano-emulsified, water-soluble CBD production capacity to many multiples of what it is today… and that is huge.”

Following the announcement of its initial pre-sale, PBIO has continued to pre-sell additional, limited quantities of the BaroShear K45. The company recently announced two additional pre-sales of the K45 system (http://ibn.fm/ExADD) – one to NanoPeak Solutions Inc., a private company located in Vancouver, British Columbia, and the second to a private company in Las Vegas, Nevada. This leaves just nine remaining systems available for the PBIO pre-sell program. Units sold over the coming weeks are on track to be delivered and installed in the first half of 2020.

“We believe that such sales will have a significant impact on 2020 total revenue, potentially resulting in more than twice the total revenue of 2019,” Schumacher stated in a news release. “We further believe that revenue from our BaroFold platform contract services will continue to increase, and that the decline in PCT platform instrument sales observed over the past two quarters (caused in part by our focus on the development of the BaroShear K45) will end, and that we will see an increase in PCT product sales over the second half of 2019, and beyond.”

Two short videos released by PBIO (http://ibn.fm/WZy4P and http://ibn.fm/9EqfO), showing how its patented UST platform is able to process CBD plant oil into a water-soluble nanoemulsion, give a quick lesson in PBIO’s proprietary technology.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Earth Science Tech Inc. (ETST) Appoints Experienced Head of New CBD Sales Division, Files Securities Registration Statement

• ETST is focused on its developing role as an international leader in the CBD space
• The company recently filed a securities registration statement with the SEC
• ETST recently named a pharmaceutical and orthopedic expert as head of its new sales division

Earth Science Tech Inc. (OTCQB: ETST) is an innovative science-based biotechnology company operating in the fields of hemp-derived cannabinoids, nutraceuticals, pharmaceuticals, medical devices and research and development (R&D). The company, based in Doral, Florida, recently announced its establishment of a new sales division specifically focusing on CBD products of therapeutic and pharmaceutical grades.

The company’s CBD (cannabidiol) oil is 100 percent natural and organic. In contrast to its competitors, which may use dangerous hemp extraction methods including toxic solvents or high heat, ETST’s CBD-rich hemp does not contain any synthetic cannabinoids and is not an isolate. Through its subsidiaries, Earth Science Tech is focused on developing its role as a world leader in the CBD space.

The impetus behind this new division comes from increased interest in CBD products across multiple medical communities, including medical, holistic and alternative medicine (http://ibn.fm/ugOM9). The division will be headed by Erika Franck, who has been serving as the company’s clinical and therapeutics sales director for several weeks. In her new role, Franck will be working with medical providers, chiropractors, acupuncturists, holistic wellness practitioners and veterinarians, utilizing her years of experience in the medical field to bring the benefits of CBD to a myriad of industries.

Franck’s expertise includes CNS (central nervous system), psychiatry, cardiology, pulmonology, asthmas, allergy and dermatology, which she cultivated through working in the pharmaceuticals and orthopedics industry for over 15 years. During her time in pharmaceuticals, Franck launched two new drugs into the medical market: Lexapro (a type of antidepressant) and Benicar (a drug used to treat high blood pressure).

“I am thrilled to be part of this amazing team and to have the opportunity to apply my expertise in spearheading this new clinical division for ETST,” Franck said in a news release. “Our shared vision is to improve patients’ quality of life, and I am honored to participate in ETST’s growth as we achieve this mission.”

ETST president, director, and chairman Nickolas Tabraue announced his excitement at adding Franck’s leadership experience to the division. “She brings a wealth of knowledge and experience to the team that will be invaluable as we pursue opportunities through this exciting new sales channel,” Tabraue added. “We pride ourselves on hiring the very best and brightest, and Erika certainly fits that criteria.”

Recently, ETST filed its Form S-1/A securities registration statement (http://ibn.fm/7ebl1). It was filed with the U.S. Securities and Exchange Commission (SEC) on September 10, 2019. The document details the company’s long-term strategy, partnerships and strategic focus, as well as providing an overview of its subsidiaries.

The company continues to expand its work in the pharmaceutical and medical device sectors through its subsidiaries, which include Nutrition Empire Inc., Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. (CTI), and KannaBidioiD (KBD). ETST also has its Canadian subsidiary, Canna Inno Laboratories Inc.

ETST continues to focus on the CBD market with its broad array of well-branded products and premier distribution. For investors, the company has a strong in-house team and strategic partnerships to foster continued growth. ETST is advancing further projects using its high-grade and inventive products.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO Discusses Company Achievements in Interview; Director of Neuroscience to Present at World Immunotherapy Congress

RJ Tesi, M.D., co-founder and CEO of clinical-stage immunology company INmune Bio (NASDAQ: INMB), was recently featured in an interview with multimedia financial reporter Jason Lin. Among other highlights, Dr. Tesi discusses recent company accomplishments in the interview. “Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,” INmune co-founder and CEO Dr. RJ Tesi stated in the interview. “We hope to continue reaching new milestones in the development of therapies that target the innate immune system.” The company also announced today that CJ Barnum, Ph.D., Director of Neuroscience, will be presenting on “Approaching Alzheimer’s disease as an immunological disease: role of biomarkers” at the World Immunotherapy Congress taking place on October 16 in Switzerland.

To view the interview, visit http://ibn.fm/298yz

To view the full press release, visit http://ibn.fm/ypk9K

About INmune Bio, Inc.

INmune Bio is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro595), and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. For more information, visit the company’s website at www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Is SRAX Inc. (NASDAQ: SRAX) and its BIGtoken Platform Building One of the Most Valuable Opted-In Data Sets in the World?

• SRAX sold its pharmaceutical arm, SRAXmd, and it continues to invest in its flourishing BIGtoken platform
• Major brands Kraft and Sun-Maid launched programs within the BIGtoken platform
• SRAX continues toward its goal of developing the largest, most valuable opted-in data set worldwide

With a platform of 16 million members that continues to grow and some of the largest consumer packaged goods brands in the country embracing SRAX Inc.’s (NASDAQ: SRAX) BIGtoken platform, the company’s third-quarter achievements are significant indicators toward attaining its goal of building the largest and most valuable opted-in data set in the world.

On the cusp of having sold its pharmaceutical arm, SRAXmd, to a group of institutional investors for $43 million (http://ibn.fm/Cj65Q), SRAX has proven that it can build value in its verticals in the past. The company utilized this profit to invest in its BIGtoken platform technology, clear its balance sheet of $12 million in debt and payables, and buy back over 700,000 shares. Additionally, SRAX retained a 31 percent ownership stake in SRAXmd at the close of the transaction, representing $10 million in preferred shares in the new entity, which is not represented on its balance sheet. This asset alone could represent a significant portion of today’s market cap of the company.

Now, it looks like SRAX’s investment in its opted-in database, BIGtoken, could not be in a better position to capitalize on the political landscape around privacy and the use of personal data. Laws are taking effect around the world that impact the way marketers are allowed to use personal data, causing those marketers to take a long hard look at the sources of their data. The SRAX solution of partnering with consumers to monetize their data could not be timelier. Traditional data providers are struggling to obtain the needed consent from consumers to keep the marketing machine going. Meanwhile, SRAX’s BIGtoken data set is positioned to become one of the most valuable consumer set on the market and could drive long term revenue value for the company. With major consumer packaged goods brands Kraft and Sun-Maid recently launching programs within the platform, BIGtoken is driving revenue.

SRAX recently reported that it had $2.5 million in cash before receiving a $5.5 million investment from existing investors. Investors should keep in mind that SRAX’s numbers for last year included revenue from the SRAXmd business, which was sold in August of last year. Though the sale of the company affected its year-over-year revenue, SRAX continues to see year-over-year and quarter-over-quarter growth without the SRAXmd business.

“We continue to build our data assets through increasing adoption of our verticals and BIGtoken,” SRAX CEO and Founder Christopher Miglino stated in a news release (http://ibn.fm/r6cDg). “These proprietary platforms are positioned to generate long-term revenue and value, while building one of the most valuable data sets in the world.”

SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html